AU2002244751B2 - Quantitative diagnostic analysis of hypertonia - Google Patents
Quantitative diagnostic analysis of hypertonia Download PDFInfo
- Publication number
- AU2002244751B2 AU2002244751B2 AU2002244751A AU2002244751A AU2002244751B2 AU 2002244751 B2 AU2002244751 B2 AU 2002244751B2 AU 2002244751 A AU2002244751 A AU 2002244751A AU 2002244751 A AU2002244751 A AU 2002244751A AU 2002244751 B2 AU2002244751 B2 AU 2002244751B2
- Authority
- AU
- Australia
- Prior art keywords
- snp
- hypertension
- hsgkl
- exon
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000004458 analytical method Methods 0.000 title description 5
- 206010020852 Hypertonia Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 79
- 206010020772 Hypertension Diseases 0.000 claims abstract description 51
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 17
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 17
- 239000002157 polynucleotide Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims description 11
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 241000282414 Homo sapiens Species 0.000 abstract description 23
- 230000004048 modification Effects 0.000 abstract description 13
- 238000012986 modification Methods 0.000 abstract description 13
- 238000003745 diagnosis Methods 0.000 abstract description 12
- 230000002018 overexpression Effects 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract description 7
- 239000002773 nucleotide Substances 0.000 abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 abstract description 4
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000969 carrier Substances 0.000 description 14
- 230000035487 diastolic blood pressure Effects 0.000 description 14
- 230000035488 systolic blood pressure Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 5
- 108091092878 Microsatellite Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010049645 Hypercatabolism Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000029215 cell volume homeostasis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010022404 serum-glucocorticoid regulated kinase Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10113876.8 | 2001-03-21 | ||
| DE10113876A DE10113876A1 (de) | 2001-03-21 | 2001-03-21 | Quantitative diagnostische Analyse der Hypertonie |
| PCT/EP2002/003180 WO2002074987A2 (de) | 2001-03-21 | 2002-03-21 | Quantitative diagnostische analyse der hypertonie |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2002244751C1 AU2002244751C1 (en) | 2002-10-03 |
| AU2002244751A1 AU2002244751A1 (en) | 2003-03-27 |
| AU2002244751B2 true AU2002244751B2 (en) | 2007-01-11 |
Family
ID=7678460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002244751A Ceased AU2002244751B2 (en) | 2001-03-21 | 2002-03-21 | Quantitative diagnostic analysis of hypertonia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060127892A1 (enExample) |
| EP (1) | EP1390531B1 (enExample) |
| JP (1) | JP2004528032A (enExample) |
| CN (1) | CN1306040C (enExample) |
| AT (1) | ATE331043T1 (enExample) |
| AU (1) | AU2002244751B2 (enExample) |
| CA (1) | CA2441314C (enExample) |
| CY (1) | CY1105566T1 (enExample) |
| DE (2) | DE10113876A1 (enExample) |
| DK (1) | DK1390531T3 (enExample) |
| ES (1) | ES2266463T3 (enExample) |
| HU (1) | HUP0303491A3 (enExample) |
| MX (1) | MXPA03008522A (enExample) |
| PL (1) | PL364387A1 (enExample) |
| PT (1) | PT1390531E (enExample) |
| RU (1) | RU2287160C2 (enExample) |
| WO (1) | WO2002074987A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003053363A2 (en) * | 2001-12-19 | 2003-07-03 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| US6830911B2 (en) * | 2002-02-08 | 2004-12-14 | Applera Corporation | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| DE10305213A1 (de) * | 2003-02-07 | 2004-08-26 | Florian Prof. Dr.med. Lang | Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms |
| JP4762552B2 (ja) * | 2003-03-03 | 2011-08-31 | フロリアン ラング、 | 診断用および治療用標的としてのｓｇｋ１ |
| DE10346913A1 (de) | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
| RU2261442C2 (ru) * | 2003-12-09 | 2005-09-27 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) | Способ диагностики артериальной гипертензии |
| WO2007025792A1 (de) * | 2005-09-02 | 2007-03-08 | Florian Lang | Verfahren zur diagnose von hypertonie |
| CN102654893A (zh) * | 2011-03-04 | 2012-09-05 | 苏州卫生职业技术学院 | 分析高尿酸血症和高血压患病率关系的方法 |
| WO2023114714A1 (en) * | 2021-12-14 | 2023-06-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Sgk1 inhibitory compositions and methods |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000062781A1 (de) * | 1999-04-20 | 2000-10-26 | Florian Lang | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk |
-
2001
- 2001-03-21 DE DE10113876A patent/DE10113876A1/de not_active Withdrawn
-
2002
- 2002-03-21 MX MXPA03008522A patent/MXPA03008522A/es active IP Right Grant
- 2002-03-21 AT AT02712954T patent/ATE331043T1/de active
- 2002-03-21 EP EP02712954A patent/EP1390531B1/de not_active Expired - Lifetime
- 2002-03-21 PT PT02712954T patent/PT1390531E/pt unknown
- 2002-03-21 JP JP2002574375A patent/JP2004528032A/ja active Pending
- 2002-03-21 HU HU0303491A patent/HUP0303491A3/hu unknown
- 2002-03-21 ES ES02712954T patent/ES2266463T3/es not_active Expired - Lifetime
- 2002-03-21 DK DK02712954T patent/DK1390531T3/da active
- 2002-03-21 RU RU2003130071/15A patent/RU2287160C2/ru not_active IP Right Cessation
- 2002-03-21 WO PCT/EP2002/003180 patent/WO2002074987A2/de not_active Ceased
- 2002-03-21 CN CNB028086481A patent/CN1306040C/zh not_active Expired - Fee Related
- 2002-03-21 PL PL02364387A patent/PL364387A1/xx not_active Application Discontinuation
- 2002-03-21 US US10/472,622 patent/US20060127892A1/en not_active Abandoned
- 2002-03-21 CA CA2441314A patent/CA2441314C/en not_active Expired - Fee Related
- 2002-03-21 DE DE50207305T patent/DE50207305D1/de not_active Expired - Lifetime
- 2002-03-21 AU AU2002244751A patent/AU2002244751B2/en not_active Ceased
-
2006
- 2006-07-28 CY CY20061101052T patent/CY1105566T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000062781A1 (de) * | 1999-04-20 | 2000-10-26 | Florian Lang | Arzneimittel enthaltend hemmstoffe der zellvolumenregulierten humanen kinase h-sgk |
| AU4297200A (en) * | 1999-04-20 | 2000-11-02 | Florian Lang | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| AU779941B2 (en) * | 1999-04-20 | 2005-02-17 | Florian Lang | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
Non-Patent Citations (2)
| Title |
|---|
| WARNTGES S et al, (2000) Kidney Blood Press Res Vol 23, p 246 * |
| WEBSTER MK et al, (1993), Mol Cell Biol, Vol 13(4), p 2031-2040 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1063338A1 (en) | 2004-12-24 |
| CN1306040C (zh) | 2007-03-21 |
| RU2003130071A (ru) | 2005-04-10 |
| CY1105566T1 (el) | 2010-07-28 |
| HUP0303491A3 (en) | 2005-12-28 |
| WO2002074987A3 (de) | 2003-12-04 |
| DK1390531T3 (da) | 2006-10-23 |
| RU2287160C2 (ru) | 2006-11-10 |
| EP1390531A2 (de) | 2004-02-25 |
| MXPA03008522A (es) | 2005-03-07 |
| CA2441314C (en) | 2011-11-08 |
| JP2004528032A (ja) | 2004-09-16 |
| AU2002244751C1 (en) | 2002-10-03 |
| US20060127892A1 (en) | 2006-06-15 |
| ATE331043T1 (de) | 2006-07-15 |
| CN1503848A (zh) | 2004-06-09 |
| PL364387A1 (en) | 2004-12-13 |
| ES2266463T3 (es) | 2007-03-01 |
| HUP0303491A2 (hu) | 2004-08-30 |
| CA2441314A1 (en) | 2002-09-26 |
| DE10113876A1 (de) | 2002-09-26 |
| EP1390531B1 (de) | 2006-06-21 |
| PT1390531E (pt) | 2006-09-29 |
| WO2002074987A2 (de) | 2002-09-26 |
| DE50207305D1 (de) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| He et al. | SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility | |
| Filigheddu et al. | Genetic polymorphisms of the β-adrenergic system: association with essential hypertension and response to β-blockade | |
| EP2155907B1 (en) | Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction | |
| Safarinejad et al. | The role of endothelial nitric oxide synthase (eNOS) T‐786C, G894T, and 4a/b gene polymorphisms in the risk of idiopathic male infertility | |
| AU2002244751B2 (en) | Quantitative diagnostic analysis of hypertonia | |
| Plummer et al. | Haplotypes of the angiotensin II receptor genes AGTR1 and AGTR2 in women with normotensive pregnancy and women with preeclampsia | |
| Qiu et al. | Genetic polymorphisms, messenger RNA expression of p53, p21, and CCND1, and possible links with chromosomal aberrations in Chinese vinyl chloride–exposed workers | |
| US20080015141A1 (en) | Use of a Novel Polymorphism in the Hsgk1 Gene in the Diagnosis of Hypertonia an Use of the Sgk Gene Family in the Diagnosis and Therapy of the Long Qt Syndrome | |
| Jira et al. | Novel mutations in the 7-dehydrocholesterol reductase gene of 13 patients with Smith–Lemli–Opitz syndrome | |
| Banno et al. | Association of genetic polymorphisms of endothelin-converting enzyme-1 gene with hypertension in a Japanese population and rare missense mutation in preproendothelin-1 in Japanese hypertensives | |
| Makiishi et al. | C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus | |
| WO2001077305A2 (en) | Variants of the human amp-activated protein kinase gamma 3 subunit | |
| EP2681337B1 (en) | Brip1 variants associated with risk for cancer | |
| JP2013520201A (ja) | 肥満症のマーカーとその使用の方法 | |
| Kamide et al. | Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations | |
| Müller et al. | SNP dependent modulation of circulating miRNAs from the miR25/93/106 cluster in patients undergoing weight loss | |
| Yamamoto et al. | Serum level and gene polymorphism of angiotensin I converting enzyme in Japanese children | |
| Sanchez et al. | STG does not associate with psoriasis in the Swedish population | |
| Schreiner et al. | Association of COMT genotypes with S-COMT promoter methylation in growth-discordant monozygotic twins and healthy adults | |
| WO2010072608A1 (en) | Pcsk1 single nucleotide polymorphism in type 2 diabetes | |
| CN102844448B (zh) | 预测hcv治疗结果的单核苷酸多态性 | |
| US8236497B2 (en) | Methods of diagnosing cardiovascular disease | |
| BULGĂR et al. | Association of TCF7L2 rs7903146 and rs290487 polymorphisms and type 2 diabetes in Romanian subpopulation | |
| Łacina et al. | Polymorphisms within genes encoding Ikaros family proteins IKZF1 and IKZF3 in multiple myeloma patients treated with thalidomide | |
| Mackawy et al. | Association of protein tyrosine phosphatase 1B (PTPN1) gene polymorphisms (1023C> A and 467T> C) with type 2 diabetes: A case-control study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2007. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 FEB 2007 |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |